Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 703 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: lenalidomide Clear all
Completed Phase 2 Interventional

Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

NCT01242930
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Imetelstat (7.5 mg/kg), lenalidomide standard of care, Imetelstat (9.4 mg/kg)
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide and High-Dose Melphalan

NCT01079936
View directory record Official record
Conditions
Myeloma, Stem Cell Transplantation
Interventions
Lenalidomide, Melphalan, Stem Cell Infusion
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

NCT01755975
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin's Lymphoma
Interventions
Romidepsin, Lenalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
7
States / cities
Hartford, Connecticut • Omaha, Nebraska • Basking Ridge, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Results available

Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

NCT01393964
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608; HuLuc63)
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

NCT01850524
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Placebo, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
78
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 4 Interventional Results available

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

NCT01731886
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Autologous peripheral blood stem cell transplant, Lenalidomide, Dexamethasone, Stem cell collection, Melphalan, G-CSF, Cyclophosphamide, Mesna
Procedure · Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 23, 2026, 10:06 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

NCT05308654
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ABBV-453, Dexamethasone, Daratumumab, Lenalidomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Stanford, California • Miami, Florida • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 23, 2026, 10:06 PM EDT
Recruiting Phase 2 Interventional

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

NCT06910124
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Linvoseltamab, Lenalidomide
Biological · Drug
Lead sponsor
Dickran Kazandjian, MD
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

NCT00536341
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
lenalidomide, Rituximab, Fludarabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT00065351
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-5013
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
26
States / cities
Glendale, Arizona • Scottsdale, Arizona • Berkeley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer

NCT00179686
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
CC-5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Metairie, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2006 · Synced Oct 23, 2026, 10:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

NCT02589145
View directory record Official record
Conditions
Lymphoma
Interventions
Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 23, 2026, 10:06 PM EDT
Terminated Phase 2 Interventional Results available

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT02128230
View directory record Official record
Conditions
Multiple Myeloma
Interventions
myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D
Device · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

NCT00445692
View directory record Official record
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Clarithromycin, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 23, 2026, 10:06 PM EDT
Active, not recruiting Phase 2 Interventional

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

NCT06112847
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review, Epcoritamab, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 10:06 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01415752
View directory record Official record
Conditions
Lymphoma, Mantle Cell Lymphoma
Interventions
rituximab, Bendamustine, bortezomib, lenalidomide
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2031
U.S. locations
416
States / cities
Anchorage, Alaska • Antioch, California • Fremont, California + 283 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

NCT02916771
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Ixazomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma

NCT01160484
View directory record Official record
Conditions
Multiple Myeloma
Interventions
DVD-R
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Bakersfield, California • Fresno, California • Loma Linda, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

NCT04196491
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bb2121, Fludarabine, Cyclophosphamide, Lenalidomide
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 23, 2026, 10:06 PM EDT
Withdrawn Phase 1 Interventional

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

NCT03373305
View directory record Official record
Conditions
CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
Interventions
Brentuximab Vedotin, Lenalidomide, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 1 Interventional

Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

NCT01132586
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Alkylating Agent-Related Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
Interventions
Lenalidomide, Cytarabine, Idarubicin, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 64 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 23, 2026, 10:06 PM EDT
Terminated Phase 1 Interventional

Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma

NCT02030483
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Palbociclib, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 23, 2026, 10:06 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

NCT02255162
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myelocytic Leukemia, Acute Myelogenous Leukemia, Acute Granulocytic Leukemia, Acute Non-Lymphocytic Leukemia
Interventions
Lenalidomide, HLA-mismatched stem-cell Microtransplantation, Cytarabine
Drug · Genetic
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 23, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide for Patients With Myelofibrosis (MF)

NCT00352794
View directory record Official record
Conditions
Myelofibrosis
Interventions
Lenalidomide, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 23, 2026, 10:06 PM EDT